Skip to main content
Top
Published in: Abdominal Radiology 5/2015

01-06-2015

Is the nonlipomatous component of dedifferentiated liposarcoma always soft tissue on CT? Analysis of CT densities and correlation with rate of growth in 60 patients

Authors: Sree Harsha Tirumani, Andrew J. Wagner, Harika Tirumani, Atul B. Shinagare, Jyothi P. Jagannathan, Jason L. Hornick, Suzanne George, Nikhil H. Ramaiya

Published in: Abdominal Radiology | Issue 5/2015

Login to get access

Abstract

Purpose

To define the various CT densities of nonlipomatous component of dedifferentiated liposarcoma (DDLPS) and to determine if the rate of growth varies with density.

Methods

This study identified 60 patients with DDPLS (38 men, 22 women; mean age at diagnosis 59 years, range, 35–82 years) who had one or more resections. CT scan immediately before the surgical resection (presurgery) and up to a maximum of one year before the surgery (baseline) was reviewed by two radiologists to note the density of the nonlipomatous elements and rate of growth during that period. Clinical and histopathological data were extracted from electronic medical records. Rate of growth of various densities was compared using Kruskal–Wallis test.

Results

Three distinct densities of the nonlipomatous component were noted: soft tissue density (SD), fluid density (FD), and mixed density (MD). Of 109 lesions on the presurgery scan (SD = 78; MD = 22; FD = 9), scans at baseline were available for 72/109 lesions (SD = 49; MD = 14; FD = 9). Median growth rate/month without treatment, with chemotherapy, and with radiotherapy were 40%, 24%, and 62%, respectively, for SD lesions and 28%, 61%, and 52% for MD lesions. For FD lesions, it was 72% and 35%, respectively, without treatment and with chemotherapy. There was no statistical difference in the rate of growth of various densities. Density changed over time in 8/72 (11%) lesions, including 2/49 SD lesions (to MD), 1/14 MD lesions (to SD), and 5/9 FD lesions (to SD).

Conclusions

DDLPS has three distinct CT densities of which soft tissue density is the most common. Despite not being statistically significant, fluid density lesions had rapid growth rate and often converted to soft tissue density in our study.
Literature
1.
go back to reference O’Regan KN, Jagannathan J, Krajewski K, et al. (2011) Imaging of liposarcoma: classification, patterns of tumor recurrence, and response to treatment. Am J Roentgenol 197:W37–W43 O’Regan KN, Jagannathan J, Krajewski K, et al. (2011) Imaging of liposarcoma: classification, patterns of tumor recurrence, and response to treatment. Am J Roentgenol 197:W37–W43
2.
go back to reference Henricks WH, Chu YC, Goldblum JR, Weiss SW (1997) Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J Surg Pathol 21:271–281PubMed Henricks WH, Chu YC, Goldblum JR, Weiss SW (1997) Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J Surg Pathol 21:271–281PubMed
3.
go back to reference Lahat G, Anaya DA, Wang X, et al. (2008) Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches. Ann Surg Oncol 15:1585–1593PubMed Lahat G, Anaya DA, Wang X, et al. (2008) Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches. Ann Surg Oncol 15:1585–1593PubMed
4.
go back to reference Ghadimi MP, Al-Zaid T, Madewell J, et al. (2011) Diagnosis, management, and outcome of patients with dedifferentiated liposarcoma systemic metastasis. Annals of surgical oncology 18:3762–3770CrossRefPubMed Ghadimi MP, Al-Zaid T, Madewell J, et al. (2011) Diagnosis, management, and outcome of patients with dedifferentiated liposarcoma systemic metastasis. Annals of surgical oncology 18:3762–3770CrossRefPubMed
5.
go back to reference Keung E, Hornick JL, Bertagnolli MM, Baldini EH, Raut CP (2013) Predictors of Outcomes in Patients with Primary Retroperitoneal Dedifferentiated Liposarcoma Undergoing Surgery. J Am Coll Surg 218(2):206–217PubMed Keung E, Hornick JL, Bertagnolli MM, Baldini EH, Raut CP (2013) Predictors of Outcomes in Patients with Primary Retroperitoneal Dedifferentiated Liposarcoma Undergoing Surgery. J Am Coll Surg 218(2):206–217PubMed
6.
go back to reference Kim EY, Kim SJ, Choi D, et al. (2008) Recurrence of retroperitoneal liposarcoma: imaging findings and growth rates at follow-up CT. Am J Roentgenol 191:1841–1846 Kim EY, Kim SJ, Choi D, et al. (2008) Recurrence of retroperitoneal liposarcoma: imaging findings and growth rates at follow-up CT. Am J Roentgenol 191:1841–1846
7.
go back to reference Hong SH, Kim KA, Woo OH, et al. (2010) Dedifferentiated liposarcoma of retroperitoneum: spectrum of imaging findings in 15 patients. Clin Imaging 34:203–210PubMed Hong SH, Kim KA, Woo OH, et al. (2010) Dedifferentiated liposarcoma of retroperitoneum: spectrum of imaging findings in 15 patients. Clin Imaging 34:203–210PubMed
8.
go back to reference Tateishi U, Hasegawa T, Beppu Y, Satake M, Moriyama N (2003) Primary dedifferentiated liposarcoma of the retroperitoneum. Prognostic significance of computed tomography and magnetic resonance imaging features. J Comput Assist Tomogr 27:799–804PubMed Tateishi U, Hasegawa T, Beppu Y, Satake M, Moriyama N (2003) Primary dedifferentiated liposarcoma of the retroperitoneum. Prognostic significance of computed tomography and magnetic resonance imaging features. J Comput Assist Tomogr 27:799–804PubMed
9.
go back to reference Gronchi A, De Paoli A, Dani C, et al. (2013) Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase I-II study from the Italian Sarcoma Group. Eur J Cancer 50(4):784–792PubMed Gronchi A, De Paoli A, Dani C, et al. (2013) Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase I-II study from the Italian Sarcoma Group. Eur J Cancer 50(4):784–792PubMed
10.
go back to reference Pawlik TM, Pisters PW, Mikula L, et al. (2006) Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol 13:508–517PubMed Pawlik TM, Pisters PW, Mikula L, et al. (2006) Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol 13:508–517PubMed
11.
go back to reference Pisters PWT, Ballo MT, Fenstermacher MJ, et al. (2003) Phase I Trial of Preoperative Concurrent Doxorubicin and Radiation Therapy, Surgical Resection, and Intraoperative Electron-Beam Radiation Therapy for Patients With Localized Retroperitoneal Sarcoma. Journal of Clinical Oncology 21:3092–3097CrossRefPubMed Pisters PWT, Ballo MT, Fenstermacher MJ, et al. (2003) Phase I Trial of Preoperative Concurrent Doxorubicin and Radiation Therapy, Surgical Resection, and Intraoperative Electron-Beam Radiation Therapy for Patients With Localized Retroperitoneal Sarcoma. Journal of Clinical Oncology 21:3092–3097CrossRefPubMed
Metadata
Title
Is the nonlipomatous component of dedifferentiated liposarcoma always soft tissue on CT? Analysis of CT densities and correlation with rate of growth in 60 patients
Authors
Sree Harsha Tirumani
Andrew J. Wagner
Harika Tirumani
Atul B. Shinagare
Jyothi P. Jagannathan
Jason L. Hornick
Suzanne George
Nikhil H. Ramaiya
Publication date
01-06-2015
Publisher
Springer US
Published in
Abdominal Radiology / Issue 5/2015
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-014-0267-x

Other articles of this Issue 5/2015

Abdominal Radiology 5/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine